| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
CureVac N.V. (NASDAQ:CVAC) shares are trading higher on Friday.
The company announced interim data from the ongoing Phase 2 study assessing monovalent and bivalent modified vaccine candidates against COVID-19.
Both vaccine candidates are being developed in collaboration with GSK Plc (NYSE:GSK).
Results from the formal interim analysis showed that both vaccine candidates using CureVac's proprietary second-generation mRNA backbone produced meaningful immune responses.
They also produced favorable reactogenicity profiles across all tested doses, including the lowest tested dose.
Also Read: Acuitas Challenges CureVac in Legal Tussle Over COVID-19 Vaccine Technology
All three of the dose levels tested were below those used in mRNA-based COVID-19 vaccines licensed in the U.S. and EU.
"These positive Phase 2 data continue to strongly validate the competitiveness of our proprietary mRNA-technology platform and second-generation mRNA backbone in comparison to a licensed mRNA-based vaccine," said Myriam Mendila, Chief Development Officer of CureVac.
The study is being conducted in Australia and is fully enrolled with 427 healthy adults aged 18 and older equally randomized between dose groups.
"With this, we advance our joint COVID-19 development program along with our joint flu vaccine program, which continues to progress steadily as well," Mendila added.
Read Next: United Microelectronics Faces Sales Slump: December Sees 18.94% Drop
Price Action: CVAC shares are trading higher by 4.232% to $4.3988 on the last check Friday.
Photo via Company
